Pacira Biosciences (PCRX) FCF Analysis: 13% Yield, SBC Drag

FCF Performance Summary

Market Cap: ~$1.01B  |  Enterprise Value: ~$1.12B  |  Price: $25.36 (as of September 11, 2026)

Cash Generation Quality

FCF converted to 112% of adjusted net income in FY2025 ($136.7M against $122.3M), a ratio that has held above 95% every year since 2022. That is a cleaner bridge between non-GAAP earnings and cash than most companies in this size range produce, and it means the adjusted profit figure Pacira reports is backed by actual cash rather than accounting adjustments that never show up on the cash flow statement. Using the standard FCF formula of operating cash flow minus capital expenditures, Pacira's own reported FCF line ties to that arithmetic to the decimal in every actual year, with no capitalized contract costs or lease reclassifications inflating the number.

Owner earnings tell a different story. Stock-based compensation ran $57.5M in FY2025 against $136.7M of FCF, meaning 42% of the cash the business generated came with a dilution cost attached. FCF after SBC was $79.2M in 2025 and has averaged just $91M annually over 2022–2025, well below the $137M headline figure. This is not a rounding issue; it roughly halves the trailing FCF yield from 13.1% to something closer to 7.6% on an owner-economic basis.

FCF/OCF conversion sat at 90% in FY2025, consistent with the 90–94% range Pacira has held since capital spending normalized. Capital expenditures fell from 8.5% of revenue in FY2021, when the large-scale EXPAREL manufacturing buildout was underway, to 2.1% in FY2025, a business that no longer needs to reinvest heavily in physical capacity to sustain current volumes.

FY2025 Capital Allocation Breakdown

Pacira deployed more than three times its FY2025 FCF to debt paydown and buybacks combined, retiring the 0.75% convertible notes due 2025 and repurchasing $150M of stock at an average price near $24 per share. That gap between deployment and FCF generation was funded by drawing the cash and short-term investments balance down from $484.6M to $238.4M, a $246M reduction, a deliberate, one-time balance-sheet cleanup rather than a sign of cash strain since the company entered the year meaningfully over-capitalized. Continuing buybacks at the 2025 pace would exceed after-SBC FCF of roughly $91M annually, so the current run rate depends on either an FCF recovery or a smaller remaining cash cushion.

5-Year FCF Trend Analysis (FY2021–FY2025)

The trajectory is a clean multi-year compounding run that peaked in 2024 and then reversed on a cost problem, not a capital-spending or revenue problem.

         FY2021      FY2022      FY2023      FY2024      FY2025
         $79.9M      $115.2M     $139.5M     $178.8M     $136.7M

  5Y CAGR: 14.3%  |  3Y CAGR: 5.9%  |  5-Yr Avg: $130.0M

Trend Narrative

From FY2021 to FY2024, free cash flow more than doubled from $79.9M to $178.8M on two mechanical drivers: capital spending collapsed as the EXPAREL manufacturing capacity buildout finished, and the elimination of a royalty obligation on EXPAREL sales removed a recurring cash drag that management specifically flagged as a 2025 margin tailwind. Neither driver required revenue growth to work: capex fell from $45.9M to $10.6M over the period while revenue grew from $541.5M to $701.0M, so FCF margin expanded from 14.7% to 25.5% almost entirely on the cost side of the ledger.

FY2025 broke that pattern. FCF fell 23.6% to $136.7M even as revenue grew 3.6% to $726.4M, and the cause sits entirely in operating cash flow rather than capital spending; CapEx was flat near 2% of revenue. Adjusted EBITDA dropped from $223.9M to $186.5M as SG&A rose roughly $32M, driven by commercial and market-access expansion plus, per the CFO, unanticipated business development, due diligence, and litigation costs in the fourth quarter. Revenue grew; cash profitability did not.

The most recent data point is a business whose capital efficiency is structurally better than it was in 2021, but whose operating cost base is currently absorbing more of each incremental revenue dollar than it did at the 2024 peak. Consensus estimates a rebound to the mid-$150M to $200M range for FY2026, which would still sit below the 2024 high.

Operating Cash Flow and D&A Context

GAAP net income is not a useful lens on this business in isolation. It swung from -$99.6M in FY2024 to a barely-positive $7.0M in FY2025 largely on amortization of acquired intangibles, a recurring, structural non-cash charge rather than a one-time item. The gap between free cash flow and net income here is a case study in why FCF is the more stable metric for a company with a heavy intangible-amortization schedule.

Capital Expenditure Profile

CapEx/D&A of 158% in FY2021 identifies exactly when the manufacturing buildout was active, spending well above depreciation to add capacity. Every year since, CapEx has run at 13–33% of D&A, meaning the company is spending a fraction of what it depreciates just to maintain current operations. That is a low-capital-intensity profile now, though it also means most of the FCF improvement since 2021 has already been captured; there is no further capex-cutting lever left to pull.

FCF Quality Score: 6/10 — Clean Conversion, Diluted Ownership

Pacira earns a 6/10 on FCF quality. The cash conversion mechanics are genuinely strong: a 90%+ FCF/CFO ratio, capital expenditures at 2% of revenue, and an FCF figure that reconciles exactly to operating cash flow minus capex with no definitional adjustments. Few small-cap specialty pharmaceutical companies produce cash this cleanly. What holds the score out of the top tier is composition, not mechanics: stock-based compensation consumed 42% of FY2025 FCF, and 2026 guidance holds that dollar figure flat against a revenue base growing only in the low single digits, meaning the dilution cost rises as a share of cash generated if growth disappoints.

The primary strength is the combination of low reinvestment needs and a de-levering balance sheet. Net debt fell from roughly 2.1x EBITDA in 2021 to under 1x by mid-2026, funded entirely from internally generated cash rather than asset sales or equity issuance, and the company retired its 2025 convertible notes on schedule. FCF/adjusted net income above 95% every year since 2022 confirms the non-GAAP profit figure is cash-backed rather than the product of aggressive add-backs.

The primary consideration is concentration layered on top of the SBC drag. EXPAREL alone drove roughly 79% of FY2025 revenue and that share is rising after the July 2026 divestiture of the iovera° cryoneurolysis business, so nearly all of Pacira's free cash flow now depends on a single product's reimbursement economics. ZILRETTA, the second product, has been flat to modestly growing for two years despite a dedicated sales force, offering little diversification if EXPAREL volume growth continues decelerating from its current mid-single-digit pace.

The specific risk that could structurally impair FCF is the NOPAIN Act's separate Medicare reimbursement mechanism, which sunsets at the end of 2027. If neither a CMS rulemaking path nor congressional action replaces it, hospitals could revert to bundling EXPAREL into a single surgical payment, compressing the per-unit economics that currently make the outpatient business work. A second, related risk is that SG&A growth continues outpacing revenue growth: adjusted EBITDA already fell from $223.9M to $186.5M in FY2025 even as revenue grew, which would keep pulling operating cash flow down independent of anything happening in capital spending.

Forward Outlook: Key Scenarios

The primary variable determining Pacira's FCF trajectory through 2027 is whether commercial payers and government reimbursement policy replace the NOPAIN Act's separate-payment mechanism before it lapses at the end of 2027.

Scenario probability estimates are illustrative only and do not constitute forecasts or price targets.

Catalysts to Monitor

The NOPAIN Act's end-2027 sunset is the single largest binary event in this analysis. Management has indicated it is pursuing both a CMS rulemaking path and a congressional path, with resolution expected roughly twelve months before the deadline, meaning the market likely gets clarity sometime in late 2026 or 2027, not immediately.

EXPAREL volume growth has decelerated for four consecutive quarters, from 9% to 7% to 7% to 4%, which management attributes to a temporary vial-mix shift and discounting from a new group purchasing organization contract. Whether that growth re-accelerates once the GPO contract anniversaries in mid-2026 is a near-term, observable test of management's explanation.

Commercial payer coverage, meaning lives with separate reimbursement outside the surgical bundle, grew from roughly 90 million to more than 150 million between the third quarter of 2025 and the second quarter of 2026, including a UnitedHealthcare agreement covering roughly 40 million lives. Continued progress toward the stated 160 million year-end goal would support the thesis that commercial payers can substitute for NOPAIN's mechanism even if the legislation lapses.

Three pipeline readouts are expected around year-end 2026: Phase 2 data for PCRX-201, a gene therapy for knee osteoarthritis, ZILRETTA's Phase 3 trial in shoulder osteoarthritis, and a registrational study for iovera° in spasticity. None of these contribute to current cash flow and all are currently a cost, but a positive readout would be the first indication that Pacira has a second product beyond EXPAREL and ZILRETTA.

Overall Assessment: PCRX FCF Quality Score 6/10

Pacira Biosciences generates free cash flow cleanly: a 90%+ FCF/CFO conversion rate, capital spending down to 2% of revenue, and an FCF figure that reconciles exactly to cash flow from operations minus capex in every actual year. The gap between that mechanical quality and the company's 13.1% headline FCF yield is stock-based compensation: 42% of FY2025's $136.7M in FCF was SBC, and the owner-economic yield after removing it falls closer to 7.6%, which is roughly where a fairly-priced, single-product specialty pharmaceutical company with a defined reimbursement risk should trade.

The five-year pattern shows a business that captured nearly all of its available capital-efficiency gains between 2021 and 2024, then hit a cost-side air pocket in 2025 that had nothing to do with capex or revenue. Whether 13.1% is actually a "good" FCF yield depends heavily on which FCF figure is being yielded. The market's willingness to pay a lower multiple for the pre-SBC number reflects a reasonably efficient read of the dilution cost, not a pricing error. The concentration in a single product facing a 2027 reimbursement cliff is the risk that sits underneath both the score and the valuation.

A 6/10 FCF Quality Score reflects genuinely strong conversion mechanics offset by a material, disclosed dilution cost and a binary regulatory catalyst that has not yet resolved. Readers building a broader framework for evaluating cash generation across companies can review how to assess FCF quality for the underlying methodology, and compare Pacira against other names using the FCF screener.

⚠️ Disclaimer: This analysis is for educational and informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any recommendation to buy, sell, or hold any security. All financial data is sourced from publicly available SEC filings and is believed to be accurate as of the analysis date but has not been independently audited. Actual results may differ materially from any scenario estimates presented. FCF calculations use operating cash flow minus capital expenditures; alternative definitions may yield different results. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal.

Data Sources

• Pacira Biosciences Annual Reports (10-K): FY2021–FY2025, SEC EDGAR XBRL (data.sec.gov)
• Pacira Biosciences Investor Relations Press Releases and Earnings Call Transcripts (Q3 2025–Q2 2026)
• Market capitalization, enterprise value, and share price as of September 11, 2026; long-term debt figure per XBRL differs from the Bloomberg-measure total debt cited for capital allocation context, reflecting different debt-classification methodologies